The median wait time between referral and appointment was 34 days, and 18 percent of patients waited more than 90 days, the study found.

A recent study reveals that Medicare Advantage plans, despite costing more, do not provide significantly more dental, vision, and hearing benefits compared to traditional Medicare. The research highli

Medicare recipients who take expensive prescriptions will get a break this year with a $2,000 cap on drug costs. The cap will reduce out-of-pocket spending for potentially millions of older Americans in Medicare Part D, which covers pharmacy or mail-order ...

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

The government is expected to pay lower prices for Ozempic and Wegovy starting in 2027. The Trump administration will decide whether to expand coverage for millions of Americans.

CHARLOTTESVILLE, Va. (WVIR) - Weight loss and diabetes drugs such as Ozempic and Wegovy could possibly be covered by Medicare in the future. It was listed with 15 other drugs to have a price negotiated. The government and manufacturers will have to negotiate a deal for the popular weight loss drugs.

List of drugs account for $41 billion in annual Medicare spending, the Biden administration said.

Popular weight loss and diabetes drugs like Ozempic and Wegovy have been added to Medicare’s list of medications that will be negotiated directly between the government and drug manufacturers, the Biden administration said Friday.

The Biden administration says popular weight loss drugs like Ozempic and Wegovy have been added to Medicare’s list of medications that will be negotiated directly between the government and drug manuf

Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for Medicare price negotiations for 2027, the U.S. government said on Friday, part of a law pharmaceutical companies have pledged to revisit with the Trump administration.

Drugs used to treat cancer, diabetes and other chronic conditions are among 15 picked for negotiations that could result in lower prices for patients, the Department of Health and Human Services confirmed Friday.